Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
-
BUSINESS Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
-
REGULATORY DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
-
BUSINESS Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
-
BUSINESS Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
-
BUSINESS Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
-
BUSINESS Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
-
REGULATORY More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
-
REGULATORY Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
-
ORGANIZATION Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
-
ORGANIZATION JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
-
REGULATORY Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
-
ORGANIZATION Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
-
REGULATORY MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
-
BUSINESS Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
-
REGULATORY MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
-
REGULATORY MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
-
BUSINESS New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
-
ORGANIZATION New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
-
BUSINESS Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…